El interés en corto de Addex Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Addex Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Addex Therapeutics (NASDAQ:ADXN) Bolsa, Informe de interés en corto

Addex Therapeutics

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics Ltd

Marui Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MAURY#OTC">MAURY</a>) is looking for FY2024 GAAP EPS of $0.93. sees sales of $1.669 billion.

News

Guidance

MAURY

Marui Group Sees FY2024 GAAP EPS $0.93; Sees Sales $1.669B

Penske Automotive Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAG#NYSE">PAG</a>) reported quarterly earnings of $3.54 per share which beat the analyst consensus estimate of $3.29 by 7.6 percent. This is a 2.61 percent increase over earnings of $3.45 per share from the same period last year. The company reported quarterly sales of $7.72 billion which beat the analyst consensus estimate of $7.58 billion by 1.87 percent. This is a 6.15 percent increase over sales of $7.27 billion the same period last year.

Earnings

Earnings Beats

Penske Automotive Group Q4 2024 Adj EPS $3.54 Beats $3.29 Estimate, Sales $7.72B Beat $7.58B Estimate

Stifel analyst Steven Wieczynski maintains MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Buy and raises the price target from $47 to $50.

Price Target

Analyst Ratings

Stifel Maintains Buy on MGM Resorts Intl, Raises Price Target to $50

Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) reported quarterly earnings of $1.01 per share. This is a 21.69 percent increase over earnings of $0.83 per share from the same period last year. The company reported $19.426 million in sales this quarter. This is a 99.92 percent decrease over sales of $24.518 billion the same period last year.

Brookfield Q4 2024 Adj. EPS $1.01 Up From $0.83 YoY, Sales $19.426M Down From $24.518B YoY

American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.22 by 1.64 percent. This is a 0.81 percent increase over earnings of $1.23 per share from the same period last year. The company reported quarterly sales of $4.70 billion which missed the analyst consensus estimate of $4.88 billion by 3.70 percent. This is a 2.60 percent increase over sales of $4.58 billion the same period last year.

Earnings Misses

American Electric Power Q4 2024 Adj EPS $1.24 Beats $1.22 Estimate, Sales $4.70B Miss $4.88B Estimate

<ul>
<li>Entering into $250 million accelerated share repurchase plan</li>
</ul>
 &nbsp;

Buybacks

Global Payments Board Approved A $250M Accelerated Share Buyback Plan

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and raises the price target from $68 to $71.

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $71

Hyatt Hotels Q4 2024 Adj. EPS $0.42 Misses $0.78 Estimate

Global Payments Q4 2024 Adj. EPS $2.95 Misses $2.96 Estimate, Sales $2.289B Miss $2.305B Estimate

Marui Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MAURY#OTC">MAURY</a>) reported quarterly earnings of $0.48 per share. This is a 9.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported $419.03 million in sales this quarter. This is a 6.09 percent increase over sales of $394.98 million the same period last year.

Marui Group Q3 EPS $0.48 Up From $0.44 YoY, Sales $419.03M Up From $394.98M YoY

The company is introducing 2025 adjusted EPS guidance of $6.17 to $6.42 and extending its long-term adjusted EPS growth rate of 5% to 7% through 2029 off the 2025 midpoint of $6.30. Management does not forecast reported GAAP EPS and related long-term growth rates.

Duke Energy Sees FY2025 Adj EPS $6.17-$6.42 vs $6.33 Estimate

Canaccord Genuity analyst Austin Moeller maintains Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) with a Buy and lowers the price target from $7 to $6.5.

BIOX

Canaccord Genuity Maintains Buy on Bioceres Crop Solutions, Lowers Price Target to $6.5

Needham analyst Laura Martin reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and maintains $145 price target.

Reiteration

Needham Reiterates Buy on Trade Desk, Maintains $145 Price Target

Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) reported quarterly earnings of $1.66 per share which met the analyst consensus estimate. This is a 9.93 percent increase over earnings of $1.51 per share from the same period last year. The company reported quarterly sales of $7.36 billion which beat the analyst consensus estimate of $7.33 billion by 0.47 percent. This is a 2.05 percent increase over sales of $7.21 billion the same period last year.

Duke Energy Q4 2024 GAAP EPS $1.66, Inline, Sales $7.36B Beat $7.33B Estimate

Outlook
Our guidance for 2025 is described below:
<ul>
<li>Revenue in the range of $4.2 billion to $4.4 billion</li>
<li>Adjusted EBITDA margin in the range of 11.0% to 12.0%</li>
<li>SG&amp;A expense of approximately 9.0% of revenue, inclusive of an estimated $45 million of stock-based compensation expense</li>
<li>Mid-20s effective tax rate for adjusted net income</li>
<li>Capital expenditures of approximately $140 million to $160 million</li>
</ul>

Granite Expects 2025 Revenue Of $4.2B-$4.4B Vs. $4.255B Consensus, And Sees Adjusted EBITDA Margin Of 11% -12%

Gopi Chande, Chief Financial Officer said, "For 2025, our revenue outlook reflects the dynamics and volatility we're seeing in the industry, with strong early signs of demand across our Digital Solutions service line. Our margin expectations assume further stabilization as well as investments to support our return to organic growth."

TIXT

TELUS Digital Expects FY25 Revenue Growth Of Approximately 2% On An Organic Basis, Adjusted EPS Of $0.32 (Est $0.35)

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $298 to $265.

BIIB

Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to $265

Sally Beauty Holdings Issues Q2 Outlook: Sees Comparable Sales To Be Approximately Flat Compared To Prior Year; Adjusted Operating Margin Is Expected To Be In Range Of 8%-8.3%

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and maintains $51 price target.

ATRC

Needham Reiterates Buy on AtriCure, Maintains $51 Price Target

TELUS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.11 by 63.64 percent. This is a 2.27 percent increase over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $3.85 billion which beat the analyst consensus estimate of $3.75 billion by 2.67 percent. This is a 0.73 percent increase over sales of $3.82 billion the same period last year.

TELUS Q4 Adj $0.18 Beats $0.11 Estimate, Sales $3.85B Beat $3.75B Estimate

Addex stock rallies 45% on Indivior collaboration update

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Addex Therapeutics (ADXN – Research Report) and keeping the price target at $...

Positive Outlook for Addex Therapeutics: Significant Collaboration Payments and Promising Pipeline Drive Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Addex Therapeutics (ADXN – Research Report) and Avid...

Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)

Shares of Addex Therapeutics ($ADXN) have rallied in the past few days, soaring by 43%, after the company announced the selection of clinical candi...

Clinical Collaboration Ignites Addex Therapeutics (ADXN) Stock Rally

Addex Therapeutics reports H1 results

Addex Therapeutics GAAP EPS of CHF0.08, revenue of CHF0.12M

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Addex Therapeutics (ADXN – Research Report), with a price...

Comments

Addex Therapeutics

Interés en corto

Addex Therapeutics (NASDAQ:ADXN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL